Related Experiment Video
Updated: Nov 7, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review
Pamela Czajka1, Alex Fitas1, Daniel Jakubik1
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology, Warsaw, Poland.
Abstract:
MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by specific gene modifications. Platelets are the major source for circulating miRNAs, with significant regulatory potential on cardiovascular pathophysiology. MiRNAs have been shown to modify the expression of platelet proteins influencing platelet reactivity. Circulating miRNAs can be determined from plasma, serum, or whole blood, and they can be used as diagnostic and prognostic biomarkers of platelet reactivity during antiplatelet therapy as well as novel therapeutic targets in cardiovascular diseases (CVDs). Herein, we review diagnostic and prognostic value of miRNAs levels related to platelet reactivity based on human studies, presenting its interindividual variability as well as the substantial role of genetics. Furthermore, we discuss antiplatelet treatment in the context of miRNAs alterations related to pathways associated with drug response.
Insights
Circulating microRNAs (miRNAs) from platelets are key biomarkers for cardiovascular disease and antiplatelet therapy response. Their levels, influenced by genetics, offer diagnostic and prognostic insights.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- MicroRNAs (miRNAs) are small, non-coding RNAs regulating gene expression.
- Platelets are significant sources of circulating miRNAs with roles in cardiovascular pathophysiology.
- miRNAs influence platelet protein expression and reactivity.
Purpose of the Study:
- To review the diagnostic and prognostic value of circulating miRNAs related to platelet reactivity.
- To explore the role of miRNAs in cardiovascular diseases (CVDs) and antiplatelet therapy.
- To discuss the influence of genetics and interindividual variability on miRNA levels.
Main Methods:
- Review of human studies on circulating miRNA levels and platelet reactivity.
- Analysis of miRNA detection methods (plasma, serum, whole blood).
- Examination of genetic factors affecting miRNA expression.
Main Results:
- Circulating miRNAs serve as biomarkers for platelet reactivity.
- miRNA levels can predict outcomes during antiplatelet therapy.
- Interindividual variability and genetics significantly impact miRNA profiles.
Conclusions:
- Circulating miRNAs are valuable diagnostic and prognostic biomarkers in cardiovascular medicine.
- miRNAs represent potential therapeutic targets for cardiovascular diseases.
- Understanding miRNA alterations is crucial for optimizing antiplatelet treatment response.
